1-2 of 2
Cesar Nunez, MD
Close
Sort by
Journal Articles

Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Bachar Samra, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Marina Y Konopleva, MD PhD, Rita Khouri, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Cesar Nunez, MD, Tapan M. Kadia, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3819.
https://doi.org/10.1182/blood-2019-127499
Published: 2019
Journal Articles

Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial

Nitin Jain, MD, Elias J. Jabbour, MD, Patrick Zweider McKay, MDPhD, Farhad Ravandi, MBBS, Koichi Takahashi, MD, Tapan Kadia, MD, William G Wierda, MD PhD, Michael E. Rytting, MD, Cesar Nunez, MD, Keyur Patel, MD PhD, Xinyan Lu, MD, Guilin Tang, MD, Sergej Naumovich Konoplev, MD PhD, Sa A. Wang, MD, Lina Han, PhD, Beenu Thakral, MD, Kathryn G. Roberts, PhD, April Deshmukh, RN, Rebecca Garris, Msc, Jeffrey L. Jorgensen, MD PhD, Antonio Cavazos, MSc, Srdan Verstovsek, MD PhD, Guillermo Garcia-Manero, MD, Susan M. O'Brien, MD, Jorge E. Cortes, MD, Charles G. Mullighan, MBBS, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1322.
https://doi.org/10.1182/blood.V130.Suppl_1.1322.1322
Published: 2017